Concord Drugs Ltd Intrinsic Value

CONCORD · Healthcare · Current price ₹80.8

Full stock page
DocStoX fair value
₹18
low confidence
Current price
₹81
Upside to fair value
-77.1%
Verdict
Avoid
Quality score
2.8 / 10
Model it yourself — Intrinsic Value Calculator
Opens pre-filled with Concord Drugs Ltd's latest numbers.

Is Concord Drugs Ltd undervalued?

DocStoX estimates the fair value of Concord Drugs Ltd at ₹18 per share, versus the current market price of ₹81. That puts the stock about -77.1% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.

How this fair value is calculated

This estimate blends 3 independent methods: Residual income (₹32), Relative P/E (₹0), Graham floor (₹3). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.

Bear, base and bull scenarios

Our scenarios span ₹0 (bear) to ₹18 (base) to ₹32 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.

Margin of safety

Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹81 versus an intrinsic value of ₹18, Concord Drugs Ltd currently offers -77.1% of negative margin (i.e. a premium).

More on Concord Drugs Ltd

Fair ValueDCFValuationFinancial RatiosPeers

DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.